Europe Vaccines Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Vaccines Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Vaccines Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Vaccines Market Regional Analysis

6.2 Europe Vaccines Market Revenue 2016-2027 (US$ Million)

6.3 Europe Vaccines Market Forecast Analysis

7. Europe Vaccines Market Analysis – by Technology

7.1 Recombinant Vaccines

7.1.1 Overview
7.1.2 Recombinant Vaccines: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.2 Conjugate Vaccines

7.2.1 Overview
7.2.2 Conjugate Vaccines: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.3 Live Attenuated Vaccines

7.3.1 Overview
7.3.2 Live Attenuated Vaccines: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.4 Inactivated and Subunit Vaccines

7.4.1 Overview
7.4.2 Inactivated and Subunit Vaccines: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

7.5 Toxoid Vaccines

7.5.1 Overview
7.5.2 Toxoid Vaccines: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

8. Europe Vaccines Market Analysis – by Disease Indication

8.1 DTP

8.1.1 Overview
8.1.2 DTP: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.2 Influenza

8.2.1 Overview
8.2.2 Influenza: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.3 Hepatitis

8.3.1 Overview
8.3.2 Hepatitis: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.4 Respiratory Syncytial Virus

8.4.1 Overview
8.4.2 Respiratory Syncytial Virus: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

8.5 Other Diseases

8.5.1 Overview
8.5.2 Other Diseases: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

9. Europe Vaccines Market Analysis – by Route of Administration

9.1 Oral

9.1.1 Overview
9.1.2 Oral: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

9.2 Injectable

9.2.1 Overview
9.2.2 Injectable: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

9.3 Other Routes of Administration

9.3.1 Overview
9.3.2 Other Routes of Administration: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

10. Europe Vaccines Market Analysis – by Patient Type

10.1 Pediatric Patients

10.1.1 Overview
10.1.2 Pediatric Patients: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

10.2 Adult Patients

10.2.1 Overview
10.2.2 Adult Patients: Europe Vaccines Market – Revenue and Forecast, 2016-2027 (US$ Million)

11. Europe Vaccines Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe Vaccines Market Breakdown, by Key Country, 2019 and 2027 (%)
11.2.1.1 Europe Vaccines Market – Revenue and Forecast Analysis – by Country
11.2.1.1 UK: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.1.1 UK: Europe Vaccines Market Breakdown, by Technology
11.2.1.1.2 UK: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.1.3 UK: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.1.4 UK: Europe Vaccines Market Breakdown, by Patient Type

11.2.1.2 Germany: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.2.1 Germany: Europe Vaccines Market Breakdown, by Technology
11.2.1.2.2 Germany: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.2.3 Germany: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.2.4 Germany: Europe Vaccines Market Breakdown, by Patient Type

11.2.1.3 France: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.3.1 France: Europe Vaccines Market Breakdown, by Technology
11.2.1.3.2 France: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.3.3 France: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.3.4 France: Europe Vaccines Market Breakdown, by Patient Type

11.2.1.4 Russia: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.4.1 Russia: Europe Vaccines Market Breakdown, by Technology
11.2.1.4.2 Russia: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.4.3 Russia: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.4.4 Russia: Europe Vaccines Market Breakdown, by Patient Type

11.2.1.5 Italy: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.5.1 Italy: Europe Vaccines Market Breakdown, by Technology
11.2.1.5.2 Italy: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.5.3 Italy: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.5.4 Italy: Europe Vaccines Market Breakdown, by Patient Type

11.2.1.6 Rest of Europe: Europe Vaccines Market – Revenue and Forecast to 2027 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe Vaccines Market Breakdown, by Technology
11.2.1.6.2 Rest of Europe: Europe Vaccines Market Breakdown, by Disease Indication
11.2.1.6.3 Rest of Europe: Europe Vaccines Market Breakdown, by Route of Administration
11.2.1.6.4 Rest of Europe: Europe Vaccines Market Breakdown, by Patient Type

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 PFIZER INC

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Merck & Co., Inc.

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 Sanofi

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Johnson & Johnson Services, Inc

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Panacea Biotec Limited

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Astellas Pharma Inc.

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 NOVAVAX, INC.

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 VBI Vaccines Inc

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Bavarian Nordic

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe Vaccines Market